Fundraising Fox
Rivus Pharmaceuticals, Inc.
Charlottesville, US · Founded 2019 · Delaware corporation · 33 employees on LinkedIn · 5 known investors
Find your way into Rivus Pharmaceuticals, Inc.
Sign up to see every warm intro you have to Rivus Pharmaceuticals, Inc.
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Rivus Pharmaceuticals, Inc. team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Rivus Pharmaceuticals develops mitochondrial-targeted therapies to treat cardiometabolic diseases. The company's pipeline focuses on novel small-molecule and biologic drugs addressing metabolic dysfunction and cardiovascular health.
Founders & leadership
Rivus Pharmaceuticals, Inc. was founded in 2019 by Francisco Portell.
FP
Francisco PortellCo-founder & Vice President, Pharmaceutical Development
AC
Allen CunninghamFounder, Chief Operating OfficerAllen Cunningham is co-founder and COO of Rivus Pharmaceuticals, a biotechnology company developing mitochondrial-targeted therapies for cardiometabolic disease. He has over twenty years of experience with early-stage and venture-backed companies in biotechnology, renewable energy, and information technology, with expertise in operations, intellectual property, product development, licensing, and finance.
NH
Nancy HargreavesExecutive
JD
Jayson DallasChief Executive Officer & President2023–2025Jayson Dallas is a physician and executive with three decades of experience building and leading biotech and pharmaceutical organizations. He previously served as CEO of Aimmune Therapeutics, guiding the company through FDA approval and its acquisition by Nestlé Health Science, and as Chief Commercial Officer at Ultragenyx, where he established commercial operations for rare disease product launches across multiple regions.
Board
FD
DD
PE
IS
Ian SmithBoard director
RW
Rick WinninghamBoard director
Investors · 5
Medicxi✓ confirmed by Rivus Pharmaceuticals, Inc.Londonvia Francesco De Rubertis · board
How we know: the company's own site · board seat on SEC Form D · funding news · prnewswire.com · Not right? Tell us
Bain Capital Life Scienceslisted by Bain Capital Life SciencesBoston
How we know: Bain Capital Life Sciences's portfolio page · Not right? Tell us
Longitude Capitallisted by Longitude CapitalMenlo Park · $10M – $30M
How we know: Longitude Capital's portfolio page · funding news · prnewswire.com · Not right? Tell us
Also in the syndicate · 1
RxCapital
Funding
SEC filings, press & company announcements$223.5M disclosed across 4 of 5 rounds · 2019–2025
- Undisclosed amountSeries AJul 2021
Longitude Capital (lead), Medicxi (lead), RxCapital
Source ↗
▶$57MraisedJan 2025 · 7 investors · PharmaceuticalsRule 506(b)
▶$57MraisedJan 2025 · 7 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Robert SchottExecutive Officer
- Shaharyar KhanExecutive Officer, Director
- Rick WinninghamDirector
- Allen CunninghamExecutive Officer, Director
- Jayson DallasExecutive Officer, Director
- Tom O'NeilExecutive Officer
- Derek DiRoccoDirector
- Ian SmithDirector
- Erin LavelleDirector
- Francesco De RubertisDirector
- Offering amount
- $57M
- Amount sold
- $57M
- First sale
- Jan 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$66MraisedSep 2024 · 7 investors · PharmaceuticalsRule 506(b)
▶$66MraisedSep 2024 · 7 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Ian SmithDirector
- Allen CunninghamExecutive Officer, Director
- Francesco De RubertisDirector
- Derek DiRoccoDirector
- Rick WinninghamDirector
- Shaharyar KhanExecutive Officer, Director
- Jayson DallasExecutive Officer, Director
- Nancy HargreavesExecutive Officer
- Offering amount
- $66M
- Amount sold
- $66M
- First sale
- Aug 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$66MraisedSep 2024 · 7 investors · PharmaceuticalsRule 506(b)
▶$66MraisedSep 2024 · 7 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Ian SmithDirector
- Allen CunninghamExecutive Officer, Director
- Francesco De RubertisDirector
- Rick WinninghamDirector
- Nancy HargreavesExecutive Officer
- Jayson DallasExecutive Officer, Director
- Derek DiRoccoDirector
- Shaharyar KhanExecutive Officer, Director
- Offering amount
- $66M
- Amount sold
- $66M
- First sale
- Aug 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$34.5MraisedOct 2021 · 4 investors · PharmaceuticalsRule 506(b)
▶$34.5MraisedOct 2021 · 4 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Shaharyar KhanExecutive Officer, Director
- Patrick EnrightDirector
- Jayson DallasDirector
- Allen CunninghamExecutive Officer, Director
- Francesco De RubertisDirector
- Offering amount
- $35M
- Amount sold
- $34.5M
- First sale
- Mar 2019
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 3
VivusVIVUS is a pharmaceutical company developing and commercializing therapies for patients with serious medical conditions and life-limiting diseases. The company advances innovative treatments through clinical development and commercialization expertise.
Corvus PharmaceuticalsCorvus Pharmaceuticals is a biopharmaceutical company developing immunology-focused medicines that target cellular components of the immune system, with therapeutic focus on immune diseases and cancer.
RobinhoodRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Companies working in the same space as Rivus Pharmaceuticals, Inc..
In the news
Frequently asked questions
- What does Rivus Pharmaceuticals, Inc. do?
- Rivus Pharmaceuticals develops mitochondrial-targeted therapies to treat cardiometabolic diseases. The company's pipeline focuses on novel small-molecule and biologic drugs addressing metabolic dysfunction and cardiovascular health.
- Who founded Rivus Pharmaceuticals, Inc.?
- Rivus Pharmaceuticals, Inc. was founded by Francisco Portell in 2019.
- Who are Rivus Pharmaceuticals, Inc.'s investors?
- Rivus Pharmaceuticals, Inc.'s investors include Medicxi, Bain Capital Life Sciences, Longitude Capital, RA Capital.
- How much funding has Rivus Pharmaceuticals, Inc. raised?
- Rivus Pharmaceuticals, Inc. has disclosed $223.5M raised across 4 of its 5 known rounds.
- Where is Rivus Pharmaceuticals, Inc. headquartered?
- Rivus Pharmaceuticals, Inc. is headquartered in Charlottesville, US.